Choline kinase α activates the mitogen-activated protein kinase pathway by binding and positively regulating epidermal growth factor receptor, thereby enhancing the proliferative, migrative, and ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
In this important study, the authors describe the mechanisms by which CDK4/6 overexpression mediates resistance to Osimertinib in EGFR mutant lung cancer models. Their data show that CD4/6 ...
Scientists have discovered that increased expression of a novel long non-coding RNA drives glioblastoma cell growth alongside a genetic amplification found in more than half of glioblastoma tumors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results